Remotely Supervised tDCS for Slowing ALS Disease Progression
CompletedNAResults postedLast updated 7 August 2025
What this trial tests
NA trial testing Transcranial Direct Current Stimulation (tDCS) in Amyotrophic Lateral Sclerosis (ALS) in 14 participants. Completed in 1 January 2025.
Adults 18 to 80, any sex, with Amyotrophic Lateral Sclerosis (ALS). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Revised ALS Functioning Rating Scale (ALSFRS-R)Primary· Change from baseline to immediately after training and baseline to 3 months follow up.
This questionnaire evaluates function over time and disease progression in ALS patients with questions related to daily activities such as speech, swallowing, walking, etc. Scores range between 0-48 with higher scores corresponding to more function being retained.
Pre to Post
Group
Value
95% CI
Transcranial Direct Current Stimulation (tDCS)
-1
± 1.06
Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group
-7.1
± 1.56
Pre to 3 month follow up
Group
Value
95% CI
Transcranial Direct Current Stimulation (tDCS)
-3.2
± 2
Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group
-7.1
± 1.56
Gait SpeedSecondary· Change from baseline to immediately after training
Self-selected will be measured as the average walking speed from 2 trials of the 10-m walk test (10MWT).
Group
Value
95% CI
Transcranial Direct Current Stimulation (tDCS)
-0.11
± 0.1
Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group
-0.30
± 0.08
Adverse events — posted to ClinicalTrials.gov
Time frame: 24 weeks during intervention and 3-month follow-up period (total of ~36 weeks).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Transcranial Direct Current Stimulation (tDCS)
Serious: 0/7 (0%)
Deaths: 0/7
Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group
Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life. Brain stimulation has been increasingly explored as a promising neuromodulatory tool to prime motor function in several neurological disorders. We propose a novel mechanism using remotely supervised brain stimulation to preserve motor function in individuals with ALS. This project will also aim to explore the effectiveness of brain stimulation on upper and lower motor neuron mechanisms in individuals with ALS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Other trials of Transcranial Direct Current Stimulation (tDCS)
Trials testing the same drug.
NCT07411833 — tDCS for Stress and Burnout in Higher Education
· NA
· enrolling by invitation
NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder
· NA
· recruiting
NCT07333404 — Combined tDCS and Pneumatic Compression for Recovery After a 10K Run
· NA
· not yet recruiting
NCT07291791 — tDCS for Pain Modulation in Knee Osteoarthritis
· NA
· active not recruiting
NCT07116109 — Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTS
· NA
· recruiting
Other recruiting trials for Amyotrophic Lateral Sclerosis (ALS)
Currently open trials in the same condition.
NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis
· recruiting
NCT07187388 — Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neu
· NA
· recruiting
NCT07233148 — Healing ALS Registry Observational Study (HAROS)
· recruiting
NCT07257302 — Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis
· NA
· recruiting
NCT07118319 — The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Am
· Phase 1
· recruiting
Other University of Illinois at Chicago trials
Trials by the same sponsor.
NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System
· NA
· not yet recruiting
NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial
· Phase 1
· not yet recruiting
NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis
· NA
· not yet recruiting
NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention
· NA
· not yet recruiting
NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
Last refreshed: 7 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04866771.